Q32 Bio (QTTB) Stock Jumps 60% on Alopecia Drug Trial Win

TLDR

• Q32 Bio stock jumped ~60% after reporting positive 36-week data from its Phase 2a SIGNAL-AA trial for bempikibart in alopecia areata
• The trial hit its primary endpoint with a 35.3% mean reduction in SALT score in the mITT population
• 40% of patients achieved SALT-20 response at Week 36; one patient showed complete hair regrowth
• Bempikibart showed a clean safety profile — no serious or Grade 3+ treatment-related adverse events
• Q32 Bio plans to launch a registration-directed program in the first half of 2027

Q32 Bio (QTTB) stock jumped roughly 60% on Monday after the company released positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial. The data tested bempikibart in patients with severe or very severe alopecia areata.

Q32 Bio Inc., QTTB

The stock was trading up over 63% on the session, pushing the company’s market cap to around $265.5 million.

The trial enrolled 33 patients with baseline SALT scores between 50 and 100. That’s a patient population with limited treatment options and, for many, prior treatment failures.

The primary endpoint was met. The trial showed a mean 35.3% reduction in SALT score from baseline in the prespecified modified intent-to-treat (mITT) analysis.

On responder rates, 40% of patients hit SALT-20 at Week 36 in the mITT analysis. A further 44% reached SALT-30 and SALT-50. One patient achieved complete hair regrowth.

Worth noting: 36.4% of the enrolled patients had previously been treated with oral JAK inhibitors — the current standard of care. That makes the response data more meaningful.

Patients received 200mg of bempikibart weekly for four doses as a loading regimen, then 200mg every other week for the remaining 32 weeks.

Safety Profile Holds Up

On safety, bempikibart came through without any serious adverse events or Grade 3+ treatment-related events. The most common side effect was injection site reactions at 36.3%, which were mostly mild and cleared on their own.

The company also completed a Part A open-label extension, which showed long-term safety and durable or improved hair growth, supporting the case for a maintenance dosing approach.

Bempikibart is a fully human anti-IL-7Rα antibody that works by blocking IL-7 and TSLP signaling to re-regulate adaptive immune function.

Balance Sheet Tidied Up

On the business side, Q32 Bio paid off and terminated its roughly $6.8 million loan with Silicon Valley Bank on June 24, 2026. That removes a lender from the picture as the company moves toward late-stage development.

Q32 Bio said it intends to advance a registration-directed program for bempikibart in alopecia areata in the first half of 2027. Full results from Part B will be presented at a future medical meeting.

The most recent analyst rating on QTTB is a Hold with a $10.00 price target.

The post Q32 Bio (QTTB) Stock Jumps 60% on Alopecia Drug Trial Win appeared first on CoinCentral.